Sergiy Tokar

Sergiy Tokar

Auto-generated profile, based on publicly available information

Sergiy Tokar

School of Biomedical Engineering and Imaging Sciences, King’s College London, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Science Signaling
Verified
Journal Article
Closed access
JMJulia Menzel
Julia Menzel
DKDaniel Kownatzki-Danger
Daniel Kownatzki-Danger
STSergiy Tokar
Sergiy Tokar
ABAlice Ballone
Alice Ballone
KUKirsten Unthan-Fechner
Kirsten Unthan-Fechner
BSBlanche Schwappach
Blanche Schwappach
Phosphorylation alters how phospholamban binds to 14-3-3 and affects cardiomyocyte Ca 2+ signaling.

29 May 2021 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
YCYu Jin Chung
Yu Jin Chung
KPKyung Chan Park
Kyung Chan Park
STSergiy Tokar
Sergiy Tokar
TEThomas Eykyn
Thomas Eykyn
WFWilliam Fuller
William Fuller
MSMichael J Shattock
Michael J Shattock
With the ever-mounting evidence for a profound and direct effect of SGLT2 inhibitors (SGLT2is) on the heart, understanding their mechanism of action becomes increasingly important. So, we are pleased that our paper 1 published in this edition of Cardiovascular Research has generated a lively debate. 2, 3 In our work, we use a variety of methods to show that, at least in our hands, empagliflozin (EMPA) from two independent suppliers, as well as two other chemically related SGLT2is, are not potent inhibitors of the cardiac Na+/H+ exchanger-1 (NHE1) and, related to this, have no effect on intracellular Na+ concentration ([Na+]i) in the healthy heart. This is contrary to several previous reports (see references 1–4 in Zuurbier et al. 2).